)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Medical Developments International
Medical Developments International (MVP) investor relations material
Medical Developments International AGM 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.AGM 2026 summary12 Nov, 2026
Opening remarks and agenda
Mark Fladrich opened the fifth hybrid AGM after confirming a quorum; four formal resolutions followed business updates from the Chair and Interim CEO.
Anita James attended her first AGM as Interim CEO after Brent MacGregor decided to return to the U.S. following six years leading the business.
Financial performance review
FY26 revenue rose 9% to $42.6m; pain-management revenue increased 12% while respiratory revenue declined 15%.
EBIT reached AUD 0.2m, up AUD 0.3m year on year; free cash flow was AUD 4.2m, up AUD 5.8m, and cash and term deposits exceeded AUD 21m.
Australian Penthrox volumes rose 9% to 359,000 units, including 28% growth in hospitals; European in-market demand increased 18% to 382,000 units.
Board and executive committee updates
Anita James was appointed Interim CEO for continuity; the Board will assess leadership needs and search for a permanent CEO. Brent MacGregor stepped down to return to North America after six years leading the business.
Mark Fladrich served as Chair; directors listed included Russell Basser, Paul Townsend, Christine Emmanuel-Donnelly and Leon Hoare.
Russell Basser and Paul Townsend stood for re-election as Non-Executive Directors; the Board recommended both candidates.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Medical Developments International
- Leadership changes as Penthrox growth plans build on FY 2026 profitability.MVP
Investor update - Penthrox demand accelerated in Europe and Australian hospitals as cash use improved.MVPQ1 2027 TU
- Pain management drove 9% revenue growth and strong cash flow, with expanded pediatric market.MVPH2 2026
- Strong cashflow and Penthrox growth, with expanded paediatric approval in Europe and UK.MVPQ4 2026
- FY 2025 saw profit growth, board renewal, and a focus on accelerating Penthrox adoption.MVPAGM 2025
- Q1 FY25 revenue up 20% year-over-year, with margin gains and strong cash position.MVPQ1 2025
- Revenue up 33% to $20m, profit and cashflow improved, with strong segment growth.MVPH1 2025
- Revenue up 18% and EBIT breakeven, with pediatric approval and strong Pain Management growth.MVPH2 2025
- Revenue up 8% to $21.6m, driven by Pain Management growth; net loss $0.2m, cashflow positive.MVPH1 2026
Medical Developments International
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)